Rare and Orphan Disease Trials

Pediatric Exclusivity and Rare Pediatric Disease Priority Review

Posted on digi By digi

Over 50% of rare diseases affect children, yet pediatric drug development often lags due to ethical complexities, limited commercial return, and small patient populations. To address this, the U.S. Food and Drug Administration (FDA) has introduced specific regulatory incentives to promote research in rare pediatric diseases, including Pediatric Exclusivity and the Rare Pediatric Disease Priority Review Voucher (PRV) program.
Click to read the full article.

Rare and Orphan Disease Trials, Regulatory Incentives

Using Genetic Testing Networks to Identify Rare Disease Trial Candidates

Posted on digi By digi

In rare disease clinical research, one of the most significant barriers to enrollment is accurate and timely diagnosis. Many patients remain undiagnosed or misdiagnosed for years, missing critical windows of eligibility for investigational therapies. Genetic testing networks offer a game-changing solution by enabling early identification of patients based on their molecular profile.
Click to read the full article.

Patient Recruitment Challenges, Rare and Orphan Disease Trials

European Medicines Agency (EMA) Incentives for Orphan Drugs

Posted on digi By digi

Orphan drug development in the European Union (EU) is governed by Regulation (EC) No 141/2000, which was implemented in 2000 to stimulate investment into therapies for rare conditions. These incentives are administered by the European Medicines Agency (EMA) through its Committee for Orphan Medicinal Products (COMP). The primary aim is to address the treatment gap for conditions affecting fewer than 5 in 10,000 people in the EU.
Click to read the full article.

Rare and Orphan Disease Trials, Regulatory Incentives

FDA Grants and Tax Credits for Rare Disease Research

Posted on digi By digi

Developing therapies for rare diseases often involves small patient populations, high R&D costs, and uncertain return on investment. To address these challenges, the U.S. government—particularly through the FDA Office of Orphan Products Development (OOPD)—offers grants and tax incentives to reduce financial risk and stimulate innovation in rare disease research. These incentives serve as non-dilutive funding sources, enabling biotech firms, academic centers, and SMEs to carry out critical early- and mid-stage development.
Click to read the full article.

Rare and Orphan Disease Trials, Regulatory Incentives

Engaging Families and Caregivers in Rare Disease Clinical Research

Posted on digi By digi

In the context of rare diseases—many of which are pediatric, progressive, or severely disabling—patients often rely heavily on family members or caregivers for daily functioning, medical decision-making, and trial logistics. Engaging these individuals is not optional; it is essential for recruitment, retention, adherence, and ethical conduct.
Click to read the full article.

Patient Recruitment Challenges, Rare and Orphan Disease Trials

Conditional Approval Pathways for Unmet Needs

Posted on digi By digi

In the context of rare and life-threatening diseases, traditional drug approval processes—requiring full clinical trial data—may delay patient access to critical therapies. Regulatory agencies such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) offer conditional approval pathways that allow medicines to reach the market based on preliminary but promising data, especially where no existing treatment options are available.
Click to read the full article.

Rare and Orphan Disease Trials, Regulatory Incentives

Incentive Models for Rare Disease Trial Participation

Posted on digi By digi

Recruiting and retaining participants for rare disease clinical trials is a uniquely complex challenge. The small size and global dispersion of eligible patient populations, coupled with high study burdens, long durations, and frequent travel, make traditional recruitment strategies insufficient. In this context, incentives—both financial and non-financial—can serve as effective tools to boost enrollment and ensure participant retention throughout the study lifecycle.
Click to read the full article.

Patient Recruitment Challenges, Rare and Orphan Disease Trials

Accelerated Approval vs Traditional Pathways

Posted on digi By digi

Developing drugs for rare diseases involves a unique set of regulatory considerations. Given the limited patient populations and the often life-threatening nature of these conditions, regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have established expedited approval mechanisms to facilitate earlier access to promising therapies. Among these, the two most prominent are Accelerated Approval and Traditional Approval.
Click to read the full article.

Rare and Orphan Disease Trials, Regulatory Incentives

Addressing Language Barriers in Global Rare Disease Recruitment

Posted on digi By digi

Rare disease clinical trials often span multiple countries and continents in order to reach the small, geographically dispersed patient populations required for statistically meaningful studies. While global recruitment opens access, it also introduces a major challenge—language barriers. Patients and caregivers may be unfamiliar with the primary language used in study materials, informed consent forms, or clinician communication.
Click to read the full article.

Patient Recruitment Challenges, Rare and Orphan Disease Trials

Case Study: Drug Approval Through Orphan Pathway

Posted on digi By digi

The Orphan Drug Act (1983) in the U.S. and corresponding regulations in the EU were created to incentivize the development of therapies for rare diseases—conditions affecting fewer than 200,000 individuals in the U.S. or fewer than 5 in 10,000 in the EU. Regulatory incentives such as market exclusivity, tax credits, fee waivers, and grants make the orphan drug pathway an essential regulatory strategy for biotech firms targeting rare and ultra-rare conditions.
Click to read the full article.

Rare and Orphan Disease Trials, Regulatory Incentives